China Tongshi (01763) rose more than 7% in the intraday period. As of press release, it rose 6.49% to HK$9.85, with a turnover of HK$3.564,400.
The Zhitong Finance App learned that China's Tongping (01763) rose more than 7% in the intraday period. As of press release, it had risen 6.49% to HK$9.85, with a turnover of HK$3,564,400.
According to the news, on April 20, CNNC announced that for the first time, China has successfully used commercial reactors in nuclear power plants to mass-produce carbon-14 isotopes to achieve full localization of carbon-14 supply. According to reports, using commercial heavy water reactors to irradiate carbon-14 is the first medical isotope project built by the Qinshan Nuclear Power Plant, and the production technology is also the first in China. According to reports, the carbon-14 targets will be supplied to the market at the end of 2024 after separation and purification. The output can fully meet domestic demand, which will strongly drive the development of China's isotope application industry chain.
According to information, China Tongfu is a listed company under China Baoyuan under the CNNC Group. It is a leading enterprise in China's nuclear medicine industry. Its radiopharmaceuticals business for imaging diagnosis and treatment dominates the Chinese market. It is also the largest product manufacturer and supplier in the Chinese market of radioactive source products. It is the only domestic supplier of radiation source products such as cobalt [60Co] for irradiation and medical cobalt [60Co]. In October of last year, the company announced that Tomo C, the first domestically produced novel double helix tomotherapy product, was officially self-produced in mass production, filling the gap in localized production in the domestic high-end radiotherapy product market.